Results 191 to 200 of about 106,528 (297)

Hydrogen-bonded organic framework for regulating pathogenic autoantigen and oxidative stress in psoriasis treatment. [PDF]

Natl Sci Rev
Li Y, Yuan H, Cheng YL, Li QX, Cao R, Li JL, Yin Q, Lu CZ, Liu TF.   +8 more
europepmc   +1 more source

The Experience of Treatment with Calcipotriol Ointment for Patients with Psoriasis.

, 2002
林 伸和, 川島 眞
openalex   +1 more source

Unilateral Hyperkeratotic Lesions With a Sporotrichoid Pattern

JEADV Clinical Practice, EarlyView.
José González Fernández, Mariano Ara‐Martín, Francesc Felipo‐Berlanga, Diego Larrosa‐Martínez, Javier Sánchez‐Bernal   +4 more
wiley   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

Infliximab-associated bilateral nonarteritic ischemic optic neuropathy in chronic plaque psoriasis treatment. [PDF]

JAAD Case Rep
Currier J, Abraham T, Murakawa GJ.
europepmc   +1 more source

Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.

, 2016
April W. Armstrong, Ronald Vender, Leon Kircik   +2 more
openalex   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

A Randomized Controlled Trial for the Optimal Implementation of Psoriasis Treatment by Integrating Chinese and Western Medicine. [PDF]

Psoriasis (Auckl)
Yu Y, Sun X, Hu R, Xia P, Wei Y, Yang W, Huang N, Ding Y, Guo S, Yang C, Weng H, Zhang Y, Ding X, Huang Q, Zhou X, Li X, Li B.   +16 more
europepmc   +1 more source

Experience in the treatment of psoriasis patients using Apremilast, a selective signalling pathway inhibitor

, 2018
Nikolay V. Kungurov, Н. В. Зильберберг, М. М. Кохан, J. V. Keniksfest, E V Grishaeva   +4 more
openalex   +2 more sources

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source